Dea Belazi Dea Belazi

Dea Belazi, PharmD, MPH is President & CEO at AscellaHealth. For over a decade, Dea has led the development and management of AscellaHealth, a global Healthcare & Specialty Pharmacy solutions organization serving patients, life sciences manufacturers, payers, and providers, offering a comprehensive portfolio of customized, tech-enabled specialty pharmaceutical and personalized medical management services. AscellaHealth’s unique, patient-centric approach is built upon proprietary technology processes for innovative programs and services optimizing health outcomes and quality of life for patients with complex chronic conditions or rare diseases that require specialty medications and/or cell and gene therapies.

Don’t Wait—Uncover the Clinical Endpoints that Will Matter to Payers and HCPs

It’s never too early in the research and development (R&D) process to identify and ...

340B Cuts Could Impact Access to Specialty Drugs

For more than 25 years, the 340B Drug Pricing Program1 has helped safety-net facilities ...

Pharma Must Demonstrate Better Outcomes for Pay-Per-Performance

In the dramatically changing pharma industry, one key trend that overlays providers of care, ...

The World’s Most Expensive Drug

Priced at a staggering $2.125 million per patient,  Zolgensma is now the world’s most ...

Changes to Medicare Part D Continue to Evolve

With the Bipartisan Budget Act of 2018 (BBA), Congress made changes to the Medicare ...